Program
Diclofenac Sodium Gel
Also written as “Diclofenac sodium gel 1%”, “Voltaren Gel” and “Diclofenac sodium gel”.
Its studies are mostly in Keratosis, Actinic · Osteoarthritis, Knee · Osteoarthritis · Pain · Myalgia, led by 8 companies.
Drug pageDiclofenac Sodium Gel: every studyMany companies study it; this page follows only the 11 they lead. All 20 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 30 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Amzellits history only | 20 open or running | phase 1since Jul 7, 2023 | Jul 7, 2023 | none ahead |
| Akornits history only | 10 open or running | phase 3since Sep 22, 2016 | Sep 22, 2016 | none ahead |
| Encube Ethicals Pvt. | 10 open or running | phase 3since Jan 30, 2019 | Jan 30, 2019 | none ahead |
| Glenmark Pharmaceuticals Ltd. Indiaits history only | 10 open or running | phase 3since Nov 3, 2015 | Nov 3, 2015 | none ahead |
| HALEONits history only | 10 open or running | phase 4since Apr 18, 2024 | Apr 18, 2024 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 1since Dec 3, 2012 | Dec 3, 2012 | none ahead |
| Viatrisits history only | 10 open or running | phase 3since May 30, 2017 | May 30, 2017 | none ahead |
Also a collaborator on its studies: Novum Pharmaceutical Research Services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Encube Ethicals Pvt. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 30, 2019First study: phase 3 study in Keratosis, ActinicFirst studyNCT03826550 · 655 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Encube Ethicals Pvt. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03826550Keratosis, Actinic · United States | 3 | Completed | Jun 30, 2018 | 655 |
How it is read
Names in the registry
- “Diclofenac Sodium Gel”, 3 entries
- “Diclofenac sodium gel 1%”, 3 entries
- “Voltaren Gel”, 1 entry
- “Diclofenac sodium gel”, 1 entry
- “Diclofenac sodium gel 3%”, 1 entry
Conditions, from the studies’ own filings
- Keratosis, Actinic, 3 studies
- Osteoarthritis, Knee, 3 studies
- Osteoarthritis, 2 studies
- Pain, 1 study
- Myalgia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.